Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients

Inclusion Criteria: * A medical history of moderate to severe allergic rhinoconjunctivitis for house dust mite for at least 12 months (definition of allergy severity according to ARIA (Bousquet et al., 2001)) * A positive skin prick test to house dust mite Dermatophagoides pteronyssinus * Specific IgE against house dust mite Dermatophagoides pteronyssinus ≥ 0.7 kU/L * Positive response to Conjunctival Provocation Test (CPT) * Being treated with anti-allergic medication for at least 12 months prior to enrollment * For asthmatic patients: confirmed diagnosis of controlled asthma according to Global Initiative for Asthma (GINA) guidelines (steps 1-3, GINA 2014), FEV1 ≥ 80% of the patient's reference value Exclusion Criteria: * Previous immunotherapy with house dust mite allergens within the last 5 years * Ongoing immunotherapy with house dust mite allergens or any other allergens * History of severe systemic reactions and/or anaphylaxis, including to food (e.g. peanut, marine animals) or to Hymenoptera venom (e.g. bee, wasp stings) or to medication (e.g. penicillin), etc. * Partly controlled or uncontrolled asthma according to GINA guidelines (GINA 2014) * Chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second (FEV1) \< 80% of the patient's reference value (ECSC) * History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the screening